Cas:129689-30-1 (S)-4-(2-hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phenoxyacetamide manufacturer & supplier

Chemical Name:(S)-4-(2-hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phenoxyacetamide

CAS.NO:129689-30-1

Synonyms:ZD 7114 HYDROCHLORIDE;zd7114;zenecazd7114;icid7114;ZD7114HCl

Molecular Formula:C₂₂H₃₁ClN₂O₆

Molecular Weight:454.94400

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:649.1ºC at 760mmHg

Density:1.172g/cm3

Index of Refraction:1.548

PSA:98.28000

Exact Mass:454.18700

LogP:2.82010

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ZD 7114 HYDROCHLORIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ZD7114HCl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ZD 7114 HYDROCHLORIDE Use and application,zd7114 technical grade,usp/ep/jp grade.

Related News: Charles River Laboratories and AstraZeneca have maintained a strategic partnership since 2012, providing AstraZeneca with outsourced regulated safety and development support on a range of treatments and vaccines, including testing and facilitating the deployment of the vaccines Vaxzevria for COVID-19 and Fluenz for seasonal infleunza. 9-(3-((5-benzamido-3-methylpyridin-2-yl)oxy)propyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide manufacturers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. 1H-2-Benzopyran-3-ol, hexahydro-1,3,7,7-tetramethyl-4-methylene- suppliers He joins us at a pivotal time as our Jinkō® platform goes from strength to strength as we expand our portfolio of partnerships. Grégoire’s strategic and operational expertise will be a vital part of our future success in accelerating and de-risking clinical trials. (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(3-(3-methoxy-2-methylacryloyl)thioureido)tetrahydro-2H-pyran-3,4,5-triyl triacetate vendor & factory A strategic CDMO partner who can uphold a strong product manufacturing approach can positively influence timeline, quality, and costs of bringing the drug to market. ,The new R&D People and Culture Strategy aims to make UK the most ideal place for research and innovation, led by individuals, universities and businesses, and funders.